CompletedInterventionalPhase 3Updated Mar 24, 2015
A Dose Ranging Study to Evaluate Safety and Efficacy of Bromfenac Ophthalmic Solution in Dry Eye Disease | NCT01212471 | Trialant
CompletedInterventionalPhase 3Updated Sep 4, 2020
A Dose Ranging Study to Evaluate Safety and Efficacy of Bromfenac Ophthalmic Solution in Dry Eye Disease
ClinicalTrials.gov ID
NCT01212471
Lead Sponsor
Bausch & Lomb IncorporatedINDUSTRY
Overall Status
Completed
Study Type
Interventional
Phase
Phase 3
Enrollment
840Actual
Last Update Posted
Sep 4, 2020Actual
Start Date
Sep 2010
Primary Completion Date
Aug 2011Actual
Completion Date
Dec 2011Actual
Brief Summary
A dose ranging study to evaluate safety and efficacy of bromfenac ophthalmic solution in dry eye disease.
Dry Eye Syndrome
Bromfenac Ophthalmic Solution A
Bromfenac Ophthalmic Solution B
Placebo Comparator
Ages Eligible for Study
Adult (18-64)Older Adult (65+)
Sexes Eligible for Study
All
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Be of either gender and any race 18 years or older
Exclusion Criteria:
Have a local or systemic disease that could interfere with the assessment of safety or efficacy or that is likely to result in early discontinuation from the study